Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07K16/10

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/132772MONOCLONAL ANTIBODIES SPECIFIC FOR THE PB2 ANTIGEN OF THE HUMAN INFLUENZA VIRUS (FLU), NUCLEOTIDE SEQUENCES, METHOD AND DIAGNOSTIC KIT FOR FLU INFECTION
WO 02.07.2020
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No PCT/CL2019/050155 Applicant PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE Inventor KALERGIS PARRA, Alexis Mikes
The invention relates to the generation of monoclonal antibodies, or fragments of same, which recognises the PB2 protein of the human influenza virus (flu), wherein the monoclonal antibodies or fragments of same comprise a variable domain of the heavy chain and a variable domain of the light chain. Also provided is a diagnostic method for detecting flu infections in biological samples of nasopharyngeal secretions, using the monoclonal antibodies in the format of a diagnostic kit.
2.WO/2020/132774MONOCLONAL ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF THAT BINDS TO THE L PROTEIN OF THE HUMAN PARAINFLUENZA VIRUS (PIV); METHOD AND KIT FOR DETECTING PIV
WO 02.07.2020
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No PCT/CL2019/050157 Applicant PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE Inventor KALERGIS PARRA, Alexis Mikes
The invention presents the generation of monoclonal antibodies, or fragments thereof, which recognise the L protein of the Human Parainfluenza Virus (PIV), wherein said monoclonal antibodies or fragments thereof comprise a variable region of the heavy chain and a variable region of the light chain. A diagnosis method for infection by PIV in a biological sample is also provided, which uses the monoclonal antibodies in diagnostic kit format.
3.20200197510RESPIRATORY VIRUS VACCINES
US 25.06.2020
Int.Class A61K 39/155
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
155Paramyxoviridae, e.g. parainfluenza virus
Appl.No 16805587 Applicant ModernaTX, Inc. Inventor Giuseppe Ciaramella

The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

4.20200200749ANTIBODY-MEDIATED NEUTRALIZATION OF EBOLA VIRUSES
US 25.06.2020
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 16790658 Applicant VANDERBILT UNIVERSITY Inventor James E. CROWE, Jr.

The present disclosure is directed to antibodies binding to and neutralizing ebolavirus and methods for use thereof. The present disclosure is directed to a method of detecting an ebolavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Table 2, or an antibody fragment thereof; and (b) detecting ebolavirus glycoprotein in said sample by binding of said antibody or antibody fragment to antigen in said sample. In still further embodiments, the present disclosure concerns immunodetection kits for use with the iminunodetection methods described above.

5.WO/2020/132091ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF
WO 25.06.2020
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No PCT/US2019/067216 Applicant HUMABS BIOMED SA Inventor CORTI, Davide
The present disclosure relates to antibodies, and antigen binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and can neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The present disclosure also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to fusion proteins that comprise the antigen binding fragments, and to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the present disclosure relates to the use of the antibodies and antibody fragments of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.
6.20200199229HUMANIZED OR CHIMERIC CD3 ANTIBODIES
US 25.06.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No 16544376 Applicant GENMAB A/S Inventor Edward Norbert VAN DEN BRINK

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

7.WO/2020/124846NEUTRALIZING ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS AND USE THEREOF
WO 25.06.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2019/080162 Applicant ZHUHAI TRINOMAB BIOTECHNOLOGY CO., LTD. Inventor LIAO, Huaxin
Disclosed are a neutralizing antibody against a respiratory syncytial virus and the use thereof. The neutralizing antibody contains a heavy chain variable region comprising VH CDR1, VH CDR2 and VH CDR3 and a light chain variable region (or named as a variable light chain domain) containing VL CDR1, VL CDR2 and VL CDR3, wherein the amino acid sequences of the VH CDR1, VH CDR2 and VH CDR3 in the heavy chain variable region are shown in SEQ ID NO.1, 2 and 3; and the amino acid sequences of the VL CDR1, VL CDR2 and VL CDR3 in the light chain variable region are shown in SEQ ID NO.4, 5 and 6. Also provided in the present invention are a nucleic acid molecule encoding the neutralizing antibody and the uses of the neutralizing antibody in the preparation of a pre-fusion protein product specifically binding to the respiratory syncytial virus, and in the preparation of a respiratory syncytial virus vaccine, etc.
8.20200199202ANTIBODY THERAPEUTICS AGAINST FILOVIRUS INFECTIONS AND USES THEREOF
US 25.06.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 16445497 Applicant ALBERT EINSTEIN COLLGE OF MEDICINE Inventor Kartik Chandran, III

Disclosed are bispecific antibodies and bispecific fission constructs that bind to Niemann-Pick C1 (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.

9.20200199204Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region
US 25.06.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 16718322 Applicant The United States of America, as represented by the Secretary, Department of Health and Human Servic Inventor Chaim Aryeh Schramm

The present invention relates anti-HIV therapies and prophylaxis. Specifically, the invention relates to broadly neutralizing antibodies against HIV-1, nucleic acids encoding these antibodies, vectors comprising the nucleic acids and cells and pharmaceutical compositions Comprising said vectors and/or antibodies. The present invention also relates to use of the antibodies and/or vectors for the treatment and/or prevention of HIV-1 infection in a subject. Furthermore, the invention also relates to a kit containing the antibodies of the invention.

10.WO/2020/132493COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING HIV-INFECTION AND/OR A RELATED CLINICAL CONDITION THEREOF
WO 25.06.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2019/067936 Applicant CLAUSS, Matthias Alexander Inventor CLAUSS, Matthias Alexander
Therapeutic compositions comprising one or more agents that inhibit the Nef-PAK2 interface, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent, and diagnose a condition/disease associated with HIV-infection or a related clinical condition thereof, are disclosed.